🔎 Trials Near Me

Domov › Burkittov limfom › Kalifornija

Klinične študije za Burkittov limfom v Kalifornija

20 študij za Burkittov limfom išče udeležence na lokacijah v Kalifornija.

Mesta v Kalifornija

Uradno besedilo študije (angleško)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Kaiser Permanente Downey Medical Center, Downey
  • Loma Linda University Medical Center, Loma Linda
  • Miller Children's and Women's Hospital Long Beach, Long Beach
  • in še 9
Vključevanje udeležencevFaza 2
366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Kaiser Permanente-Deer Valley Medical Center, Antioch
  • Community Cancer Institute, Clovis
  • UC Irvine Health Cancer Center-Newport, Costa Mesa
  • in še 26
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UC San Diego Moores Cancer Center, La Jolla
  • in še 1
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Loma Linda University Medical Center, Loma Linda
  • Miller Children's and Women's Hospital Long Beach, Long Beach
  • UCSF Benioff Children's Hospital Oakland, Oakland
  • in še 4
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital Los Angeles ( Site 1006), Los Angeles
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Kaiser Permanente-Anaheim, Anaheim
  • Kaiser Permanente Downey Medical Center, Downey
  • Kaiser Permanente-Fontana, Fontana
  • in še 14
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Kaiser Permanente Downey Medical Center, Downey
  • City of Hope Comprehensive Cancer Center, Duarte
  • Loma Linda University Medical Center, Loma Linda
  • in še 14
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital Orange County, Orange
  • UCSF School of Medicine, San Francisco
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Duarte
  • Research Site, Los Angeles
  • Research Site, Palo Alto
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT06137118

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

  • Stanford University, Palo Alto
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • City of Hope, Duarte
  • Valkyrie Clinical Trials, Los Angeles
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07069699

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

  • City of Hope Medical Center, Duarte
Vključevanje udeležencevFaza 1
Starost 12–55 · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT07133997

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Duarte
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT07109219

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

  • University of California, San Francisco, San Francisco
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT04545762

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
  • UC San Diego Moores Cancer Center, La Jolla
  • in še 1
Vključevanje udeležencevFaza 2
Starost 18–54 · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06918431

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • City of Hope, Duarte
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 5. nov. 2025 · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
Vključevanje udeležencevFaza 1/2
Starost 15–50 · Vsi spoli · Posodobljeno 9. sep. 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • City of Hope, Duarte
  • Children's Hospital Los Angeles, Los Angeles
  • UCLA Mattel Children's Hospital, Los Angeles
  • in še 2
Vključevanje udeležencevFaza 2
Starost 1–25 · Vsi spoli · Posodobljeno 4. maj 2025 · NCT03509961

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.